Press and Media
View the latest AANEM Achievement Award winners, the American Neuromuscular Foundation (ANF) Abstract Award winners, and the latest AANEM news articles on News Express.
Frequently Asked Questions
Q: When will be content of abstracts be viewable, as opposed to just the titles?
A: The abstract content will be available at the annual meeting during the Poster Hall hours. We do not provide abstract presenter information or slides ahead of time. All available information can be found in the AANEM Abstract Guide online when it becomes available.
Q: How do I reach out to abstract or session presenters for an interview?
A: We do not offer member contact information. To connect with abstract or session presenters, review the AANEM Annual Meeting Program when available. Find the topics of interest and connect with the presenter after their lecture or during their abstract poster session time. Currently there is no interview option for virtual attendees.
Q: When can I share information?
A: The embargo on the abstracts themselves is lifted when they have been published in Muscle & Nerve and online in the AANEM Abstract Guide. However, the additional information beyond what is in the abstract itself is still embargoed.
AANEM requires information that goes beyond that which is contained within the abstract, e.g., the release of data not included in the abstract, discussion of the abstract done as part of a scientific presentation, etc. to be embargoed until the start of the annual meeting. Please see the Abstract Embargo Policy.
Q: Will the Abstract Award Reception feature the best posters?
A: The Abstract Award Reception is a social hour in honor of the abstract award winners where all authors, including award winners, will be available to discuss research.
Q: Original research is ONLY presented as posters, correct?
A: Yes - the research is presented in the Poster Hall via abstract posters.
Patient Safety: Electrodiagnostic Findings After Chemodenervation
From the Quality and Patient Safety Committee
A 43 year old presents for evaluation of cervical radiculopathy. Symptoms include neck pain and radicular right arm pain. Medical history includes refractory chronic migraines that are managed by serial Onabotulinum toxin A injections using standard protocol. Electrodiagnostic testing is requested by the spine surgery team to evaluate for the presence of a cervical radiculopathy.
Question: Which of the following statements best describes the expected EDX findings related to treatment?
A: EDX findings are supportive of a widespread neuromuscular disease
B: Decremental responses with repetitive nerve stimulation responses at low frequencies
C: Reinnervating motor unit action potentials in the right deltoid
D: Fibrillation potentials in the right upper trapezius muscles
Explanation:
The correct answer is D. Onabotulinum toxin is an effective treatment for chronic
migraine, and its use has increased since FDA approval for this indication.
Providers performing electrodiagnostic testing should be vigilant of the location
and timing of therapeutic chemodenervation when designing and interpreting data
of electrodiagnostic tests.
Onabotulinum toxin binds to SNARE proteins on the surface of
synaptic vesicles and the presynaptic membrane, which in turn prevents the
release of acetylcholine into the synaptic cleft. Persons with chronic migraine
will experience effects in the motor units injected even though this is not the
final target for the treatment. Since the motor unit is affected,
electrodiagnostic (EDX) studies of the injected muscles will demonstrate
findings consistent with a pre-synaptic neuromuscular junction lesion, similar
to systemic botulism. EDX findings that have been reported include lack of
decrement with 3 Hz repetitive nerve stimulation and facilitation with 20 Hz
repetitive nerve stimulation; progressive increasing of jitter; early
appearance of fibrillations; small and short motor unit action potential in the
first 3 weeks, followed by increasing of MUAP amplitude and duration, with
polyphasic morphology. Case reports by neuromuscular experts have also
identified similar findings in distal muscles, suggesting that some patients
experience distant spread.
These EDX findings can be seen in both patients with and without known neuromuscular disease, and have been reported to peak at 15 to 30 days post-treatment. As such, caution should be practiced when offering chemodenervation as a management option to patients with neuromuscular conditions, particularly if disease state is severe or poorly controlled.
Author: Sarah M. Jones, MD
Sources:
- Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clin Neurophysiol. 2012;123(1):54-60. doi:10.1016/j.clinph.2011.05.032
- Lispi L, Leonardi L, Petrucci A. Longitudinal neurophysiological assessment of intramuscular type-A botulin toxin in healthy humans. Neurol Sci. 2018;39(2):329-332. doi:10.1007/s10072-017-3191-3
- Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology. 1986;36(4):545-547. doi:10.1212/wnl.36.4.545
- Moron H, Gagnard-Landra C, Guiraud D, Dupeyron A.
Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following
Injection of Botulinum Toxin-A: A Narrative Review of the Literature. Toxins
(Basel). 2021 May 17;13(5):356. doi: 10.3390/toxins13050356. PMID: 34067540;
PMCID: PMC8156529.